Neeraj Narula
McMaster University
H-index: 33
North America-Canada
Top articles of Neeraj Narula
P820 Targeting MM-SES-CD< 22.5 for endoscopic improvement is feasible in a clinical trial of Crohn’s disease: A post-hoc analysis of SEAVUE
Journal of Crohn's and Colitis
2024/1/1
P409 Optimal endoscopic healing thresholds defined by MM-SES-CD< 22.5 and SES-CD< 4 are associated with low risk of disease progression in Crohn’s disease
Journal of Crohn's and Colitis
2024/1/1
P879 Comparative Efficacy of Biologics and Small Molecule Therapies for the Induction and Maintenance of Endoscopic and Histological Remission in Ulcerative Colitis: A …
2024/1/1
DOP46 Tofacitinib for hospitalized acute severe Ulcerative Colitis–the TRIUMPH study
Journal of Crohn's and Colitis
2024/1/1
P672 Occurrence of malignancy among infliximab biosimilar and bio-originator initiators in Canada: a comparative population-based analysis
Journal of Crohn's and Colitis
2024/1/1
P689 Adaptive steroid tapering impedes corticosteroid-free remissions compared to forced tapering in UC clinical trials
Journal of Crohn's and Colitis
2024/1/1
Moving towards prognostic endoscopic scoring in IBD
2024/1
Neeraj Narula
H-Index: 27
Real-world effectiveness and safety of ustekinumab in bio-naive patients with moderate-to-severe Crohn's disease: A Canadian multi-center study
Intestinal research
2023/1
Histological Remission Placebo Rates in Ulcerative Colitis Trials: A Systematic Review and Meta-analysis
2024/1/1
Neeraj Narula
H-Index: 27
Comparing the efficacy of vedolizumab between males and females: a post-hoc analysis of GEMINI-1 and VARSITY
European Journal of Gastroenterology & Hepatology
2024/6/1
Neeraj Narula
H-Index: 27
Pharmacological therapies for the management of fistulizing Crohn’s disease: a systematic review and meta-analysis
2024/4/1
Endoscopic and Histological Placebo Rates in Crohn’s Disease Clinical Trials: A Systematic Review and Meta-analysis
2024/4/1
A273 A PILOT PROSPECITVE, MULTI-CENTRE, RANDOMIZED CONTROLLED TRIAL COMPARING FECAL MICROBIOTA TRANSPLANTATION (FMT) TO PLACEBO AT INDUCING REMISSION IN MILD TO MODERATE CROHN …
Journal of the Canadian Association of Gastroenterology
2024/3
A252 DRUG DISCONTINUATION AND PERSISTENT SYMPTOMS AMONG THE USERS OF BIOSIMILAR AND LEGACY ANTI-TNF DRUGS IN A REAL-WORLD CANADIAN IBD COHORT
Journal of the Canadian Association of Gastroenterology
2024/3/1
A113 COVID-19 VACCINATIONS IN IBD PATIENTS: PATIENT KNOWLEDGE AND PERCEPTIONS
Journal of the Canadian Association of Gastroenterology
2024/3/1
A278 ACCEPTABILITY, FEASIBILITY, AND IMPACT OF THE MYGUT DIGITAL HEALTH PLATFORM IN THE MONITORING AND MANAGEMENT OF INFLAMMATORY BOWEL DISEASE
Journal of the Canadian Association of Gastroenterology
2024/3/1
Predicting endoscopic improvement in ulcerative colitis using the ulcerative colitis severity index
Inflammatory Bowel Diseases
2024/3/1
Vipul Jairath
H-Index: 38
Neeraj Narula
H-Index: 27
Defining Endoscopic Remission in Crohn’s Disease: MM-SES-CD and SES-CD Thresholds Associated with Low Risk of Disease Progression
Clinical Gastroenterology and Hepatology
2024/2/28
Matching-adjusted Indirect Comparisons vs Propensity Score Matching with Individual Patient-level Data to Estimate Treatment Efficacy
Inflammatory Bowel Diseases
2024/2/1
Vipul Jairath
H-Index: 38
Neeraj Narula
H-Index: 27
Efficacy and Safety of Upadacitinib During Induction in Crohn’s disease: Real-World Experience
2024/1/24
Waqqas Afif
H-Index: 20
Neeraj Narula
H-Index: 27
